Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 17/20 | 0.55 |
| ▸ | PRKAA1 | Q13131 | 17/20 | 0.55 |
| ▸ | PRKAB1 | Q9Y478 | 17/20 | 0.55 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.54 |
| ▸ | PRKAB2 | O43741 | 16/20 | 0.45 |
| ▸ | PRKAA2 | P54646 | 16/20 | 0.45 |
| ▸ | PRKAG3 | Q9UGI9 | 16/20 | 0.45 |
| ▸ | PRKAG2 | Q9UGJ0 | 16/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4932564 | 0.89 | PRKAG1 (0.45) | PRKAG1PRKAA1PRKAB1HAO1PRKAB2 | |
| SCHEMBL11971138 | 0.86 | PRKAG1 (0.45) | PRKAG1PRKAA1PRKAB1HAO1PRKAB2 | |
| SCHEMBL6195016 | 0.85 | DYRK1A (0.44) | PRKAG1PRKAA1PRKAB1HAO1 | |
| SCHEMBL1141823 | 0.81 | KDM4E (0.63) | PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL19001429 | 0.81 | YTHDC1 (0.63) | — | |
| SCHEMBL4295771 | 0.81 | CDC7 (0.47) | PRKAG1PRKAA1PRKAB1HAO1 | |
| SCHEMBL4008217 | 0.81 | PRKAG1 (0.56) | PRKAG1PRKAA1PRKAB1HAO1PRKAB2 | |
| SCHEMBL14792020 | 0.81 | PRKAG1 (0.56) | PRKAG1PRKAA1PRKAB1HAO1PRKAB2 | |
| SCHEMBL1963463 | 0.81 | PRKAG1 (0.56) | PRKAG1PRKAA1PRKAB1HAO1PRKAB2 | |
| SCHEMBL9909088 | 0.80 | PRKAG1 (0.40) | PRKAG1PRKAA1PRKAB1HAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | ASTEX TECHNOLOGY, INC. (GB) | 2006-06-22 | — | — | US | claimed |
| JP-2006500348-A | — | — | 2006-01-05 | — | — | JP | claimed |
| EP-1534685-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | Astex Technology Limited (GB) | 2005-06-01 | — | — | EP | claimed |
| WO-2004014864-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-02-19 | — | — | WO | claimed |
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| CN-119968362-A | Indazole derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-05-09 | — | — | CN | disclosed |
| WO-2023230540-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023230540-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-3755696-B1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20230047396-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| US-20220402921-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2022-12-22 | — | — | US | disclosed |
| EP-1720856-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1679308-A1 | NOVEL INDAZOLE DERIVATIVE | Ube Industries, Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | ASTEX TECHNOLOGY, INC. (GB) | 2006-06-22 | — | — | US | disclosed |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2006-01-05 | — | — | US | disclosed |
| WO-2005077050-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
| EP-1534685-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | Astex Technology Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005014554-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS MAPKAP KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004014864-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047396-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | WNT1, WNT3, WNT3A | PRKAG1 1105/4885PRKAA1 1466/4885PRKAB1 1335/4885 |
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | WNT3, WNT3A, WNT1 | PRKAG1 1177/4885PRKAA1 992/4885PRKAB1 923/4885 |
| US-20220402921-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, DYRK3 | PRKAG1 1963/4885PRKAA1 1149/4885PRKAB1 2175/4885 |
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM2, TRPV1 | PRKAG1 1037/4885PRKAA1 2596/4885PRKAB1 1287/4885 |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | CDK2, CDK1, CDK4 | PRKAG1 2376/4885PRKAA1 1041/4885PRKAB1 3019/4885 |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | CCNC, CDK1, CDK7 | PRKAG1 3651/4885PRKAA1 2093/4885PRKAB1 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.